相关临床试验
6
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
5
83.3%
终止
1
16.7%
暂无批准数据
- Researchers have developed two new peptide compounds, GEP44 and KCEM1, that target weight loss with potentially fewer gastrointestinal side effects than current GLP-1 drugs. - These compounds partner with PYY receptors, aiming to trigger significant weight loss without the nausea and vomiting often associated with GLP-1 receptor targeting medications. - A company co-owned by Syracuse University and the University of Pennsylvania is working to commercialize the compounds, with human trials anticipated within the next year. - Experts emphasize the need for a multidisciplinary approach to weight loss, including lifestyle and nutritional interventions, to address high discontinuation rates across weight loss treatments.
- The weight loss drugs market is predicted to grow rapidly, with analysts at SNS Insider forecasting a 43.73% CAGR through 2032, driven by rising obesity rates. - Health and wellness companies like PlantX, Herbalife, and WW International are adapting by offering weight loss drugs, supplements, and comprehensive programs. - Amgen is advancing its anti-obesity asset MariTide, showing promising Phase I results with a 14.5% body weight loss by day 85 in clinical trials. - PlantX Life Inc. has partnered with LIV3 to launch SugarShield, a plant-based supplement targeting the $5.24 billion weight loss management supplement market.
